Drug Formulary Review Archives – April 1, 2007
April 1, 2007
View Archives Issues
-
Sliding (scale) down a slippery slope? Go to proactive glycemic control in pts
Hospitals and their pharmacists need to make a conscious effort to improve glycemic control in hospitalized diabetic patients, moving from a traditional reactive approach to embrace newer, protractive strategies. -
Be aware of labor and delivery complications
Hospital pharmacists who are aware of the conditions and complications requiring drug therapy during labor and delivery will be able to make knowledgeable decisions about the rapid accessibility of critical medications in the labor and delivery unit, researchers advise. -
Groups urge universal childhood flu vaccination
A broad coalition of 122 organizations representing public health, private providers, advocacy and educational groups, and persons affected by disease, has urged the Centers for Disease Control and Preventions Advisory Committee on Immunization Practices (ACIP) to move forward this year with recommendations for universal childhood vaccination against influenza to include all children and teens through age 18. -
News Briefs: Joint Commission wants hand hygiene info
The Joint Commission is seeking comprehensive, innovative, and cost effective hand hygiene measurement methods that address adherence to hand hygiene guidelines to share with health care organizations throughout the world, as part of its Consensus Measurement in Hand Hygiene (CMHH) project. -
New FDA Approvals
FDA recently announced these approvals: Grifols Biologicals' antihemophilic factor/von Willebrand factor complex (human), Alphanate, indicated for patients undergoing surgery or invasive procedures with von Willebrand disease in which the hormone desmopressin is either ineffective or contraindicated. -
Drug Criteria & Outcomes: From battlefield to hospital: Researchers ponder broader role for drug designed to stop the bleeding
In recent months different media outlets across the United States and Great Britain have reported on the use of an "unproven" drug being used on the battlefields of Iraq and Afghanistan. -
Drug Criteria & Outcomes: Telbivudine Formulary Evaluation
The thymidine moiety of telbivudine is phosphorylated by cellular kinases to active form. This triphosphate form is then capable of being incorporated into the viral DNA of HBV where inhibition of reverse transcriptase results in DNA chain termination of HBV.